The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.

Islamagic, Erna

The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. [electronic resource] - Clinical lymphoma, myeloma & leukemia 04 2017 - 238-240 p. digital

Publication Type: Journal Article; Multicenter Study

2152-2669

10.1016/j.clml.2017.02.001 doi


Adult
Antineoplastic Agents--therapeutic use
Bosnia and Herzegovina
Drugs, Generic--therapeutic use
Female
Follow-Up Studies
Humans
Imatinib Mesylate--therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Middle Aged
Retrospective Studies